Ligand Pharmaceuticals
LGND
203 hedge funds and large institutions have $1.95B invested in Ligand Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 89 increasing their positions, 68 reducing their positions, and 37 closing their positions.
94% more call options, than puts
Call options by funds: $10.5M | Put options by funds: $5.41M
31% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 68
6% less funds holding
Funds holding: 215 → 203 (-12)
12% less capital invested
Capital invested by funds: $2.23B → $1.95B (-$276M)
30% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 37
67% less funds holding in top 10
Funds holding in top 10: 6 → 2 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$46.1M |
| 2 |
RIM
RS Investment Management
San Francisco,
California
|
+$38.5M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$8.92M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.13M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$7.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
William Blair & Company
Chicago,
Illinois
|
-$130M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$16.4M |
| 3 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
-$12.3M |
| 4 |
CAM
Cortina Asset Management
Milwaukee,
Wisconsin
|
-$8.23M |
| 5 |
Morgan Stanley
New York
|
-$5.48M |
LGND Hedge Fund Activity: Q3 2015 in Review
203 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q3 2015, worth a combined $1.95B — down 12% from $2.23B a quarter earlier.
Sellers outnumbered buyers: 37 funds closed out of LGND and 26 opened new positions — a net loss of 11 holders — while 68 trimmed existing stakes and 89 added.
The largest buyer was Oak Ridge Investments, adding an estimated $46.1M. The largest seller was William Blair & Company, cutting an estimated $130M.
- 203 institutional investors held Ligand Pharmaceuticals (LGND) as of Q3 2015, down from 215 in Q2 2015.
- Funds reported $1.95B of Ligand Pharmaceuticals stock for Q3 2015, down 12% quarter-over-quarter.
- 26 funds opened new Ligand Pharmaceuticals positions in Q3 2015 and 37 closed out, a net change of -11 holders.
- The largest Ligand Pharmaceuticals buyer in Q3 2015 was Oak Ridge Investments, an estimated $46.1M added.
- The largest Ligand Pharmaceuticals seller in Q3 2015 was William Blair & Company, an estimated $130M sold.
Based on aggregated 13F filings for Q3 2015.